Nurse Practitioner in Seabrook, NH Accepting Medicare
4 Nurse Practitioner nurses found. Showing 1 - 4
 Dr. Tyler Douglas Lamson, DC Nurse Practitioner - Acute Care Medicare: May Accept Medicare Assignments Practice Location: 270 Lafayette Rd Unit 6, Seabrook, NH 03874 Phone: 603-474-9990 Fax: 603-474-9996 |
 Danielle Bouchard, PMHNP-BC Nurse Practitioner - Psych/Mental Health Medicare: Not Enrolled in Medicare Practice Location: 823 Lafayette Rd, Seabrook, NH 03874 Phone: 603-760-1942 Fax: 603-760-1949 |
Alyssia Lin, FNP-BC Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 380 Lafayette Rd # 11-195, Seabrook, NH 03874 Phone: 603-785-2601 |
Natalie Amanda Fekete, PMHNP-BC Nurse Practitioner - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 823 Lafayette Rd, Seabrook, NH 03874 Phone: 603-760-1942 Fax: 978-486-4037 |
News Archive
Depressive symptoms associated with poorer survival in patients with head and neck cancer
In a study of patients with head and neck cancer, even mild depressive symptoms were associated with poorer overall survival.
Olympus to host fifth annual neuroimaging symposium in conjunction with 2014 annual meeting of the Society for Neuroscience
Olympus is hosting its fifth annual neuroimaging symposium in conjunction with the 2014 annual meeting of the Society for Neuroscience (SfN) on Monday, November 17 at 6:30pm in Washington DC. The Olympus Neuroimaging Symposium and reception will be held at the Marriott Marquis Washington, DC, 901 Massachusetts Avenue NW, in the Capitol and Congress ballrooms. It is open to all media and registered SfN attendees.
China Botanic fourth quarter net revenue increases 12.8% to $18.8M
China Botanic Pharmaceutical Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines in China, today announced financial results for the three months and fiscal year ended October 31, 2011.
Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidity, including the development of acute lung transplant rejection in 10% to 20% of infected patients.
Low fertility causes 'very real problems' for developed nations' economies
"In recent years, nearly every demographic study has painted a dire picture of the world's changing demographics. Yet when the U.N. issued its latest report this past May, it seemed almost sunny," Jonathan Last, senior writer at the Weekly Standard, writes in a Wall Street Journal opinion piece.
› Verified 9 days ago